19 articles for J Hawkins
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
21
Synthesis and muscarinic activities of quinuclidin-3-yltriazole and -tetrazole derivatives.

Smithkline Beecham Pharmaceuticals
47
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.

Smithkline Beecham Pharmaceuticals
29
Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.

Genentech
46
A reversed sulfonamide series of selective RORc inverse agonists.

Argenta Discovery
25
Identification of tertiary sulfonamides as RORc inverse agonists.

Genentech
24
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.

AstraZeneca
40
BACE-1 hydroxyethylamine inhibitors using novel edge-to-face interaction with Arg-296.

Glaxosmithkline
19
BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs).

Glaxosmithkline
28
BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character.

Glaxosmithkline
38
Discovery of a Series of 7-Azaindoles as Potent and Highly Selective CDK9 Inhibitors for Transient Target Engagement.

AstraZeneca
35
Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.

AstraZeneca
9
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.

Smithkline Beecham Pharmaceuticals
20
Pyridine-derived γ-secretase modulators.

Glaxosmithkline Pharmaceuticals
59
Treatment of infectious diseases with glucose uptake inhibitors

Kadmon
139
Inhibiting agents for Bruton's tyrosine kinase

Biogen Ma
86
Factor IXa inhibitors

Merck Sharp & Dohme
96
N-substituted pyrazolo [3,4-D] pyrimidine ketone compound, and preparation process and use thereof

Sun Yat-Sen University
77
Rho kinase inhibitors and methods of use

H. Lee Moffitt Cancer Center and Research Institute
19
Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

Bristol Myers Squibb